NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company said its proposed clinical trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions.
NanoViricides noted that NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies can be difficult to deploy. The company also highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain.
NanoViricides said it believes NV-387’s broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains and noted that the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country for that study. For more details, visit https://ibn.fm/LaNwF.
The company’s lead drug candidate, NV-387, is a broad-spectrum antiviral drug that they plan to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials.
NanoViricides’ platform technology and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
As with any drug development efforts, there can be no assurance at this time that any of the company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
